Clinical trials · Pennsylvania
Cancer clinical trials in Pennsylvania
We’re tracking 839 recruiting cancer studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
Pittsburgh, PennsylvaniaAges 12 years+ - NCT05071937RecruitingPhase 2
Talazoparib plus ZEN003694 for recurrent ovarian cancer
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05126290Recruiting
Study for CTNNA1 gene family members
This study looks at people who carry a specific “loss-of-function” CTNNA1 gene change—or who are closely related to someone who does. It’s designed to better understand this genetic risk in families and may help guide future care and monitoring.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05198830RecruitingPhase 2
Adding TRC102 to standard chemoradiation for stage III lung cancer
This Phase 2 trial tests whether adding TRC102 to standard chemotherapy plus radiation can improve outcomes for people with stage III non-squamous, non-small cell lung cancer. It is designed for newly staged patients and aims to help the immune system work better while treating the tumor.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05427240Recruiting
Check if an online approach works for cancer gene testing
This study tests an e-health (online) way to help people get genetic testing for hereditary cancer risk. It is meant for people who have never had germline genetic testing before and may qualify for standard genetic testing based on cancer risk guidelines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05502523Recruiting
Blood test DNA levels after lung surgery
This study looks at how different lung surgical techniques affect levels of tumor DNA in the blood before and after surgery for early-stage lung cancer. It may help doctors choose surgical approaches and use a blood test to monitor cancer after surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Allentown, PennsylvaniaAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Philadelphia, PennsylvaniaAges 12 years+ - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05838716RecruitingPhase 3
Vitamin D During Hormone Therapy for Prostate Cancer
This trial studies whether taking vitamin D while you are on prostate hormone therapy (ADT) affects your health outcomes. It may help by keeping vitamin D levels in a safe range during treatment.
Scranton, PennsylvaniaAges 50 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Wilkes-Barre, PennsylvaniaAges 18 years+ - NCT06138067Recruiting
Navigator program to help cancer patients join clinical trials
This study tests if a patient navigator can help more people with prostate or kidney cancer enroll in clinical trials. You may be assigned to work with a navigator who helps find a trial that fits your needs.
Chambersburg, PennsylvaniaAges 18 years+ - NCT06228326RecruitingPhase 1/Phase 2
Study of KB707 for advanced cancers affecting the lungs
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Allentown, PennsylvaniaAges 18 years+ - NCT06515613RecruitingPhase 1
Testing CTIM-76 for recurrent ovarian and other advanced cancers
This trial tests a new drug, CTIM-76, in people whose ovarian, testicular, or endometrial cancer has come back and is not responding to standard treatments. It aims to see if the drug can shrink tumors or stop them from growing.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Sayre, PennsylvaniaAges 18 years+ - NCT06654037RecruitingPhase 1
Testing abemaciclib plus 5-FU for advanced colorectal cancer
This trial is testing whether adding a targeted drug called abemaciclib to the standard chemotherapy 5-FU can help people with a specific type of advanced colorectal cancer (MSS) that has stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06682988RecruitingPhase 2
New treatment for advanced ovarian cancer
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Doylestown, PennsylvaniaAges 18 years+
Cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting cancer studies listed above.
- UPMC Hillman Cancer Center · 8 studies
- University of Pennsylvania · 4 studies
- Fox Chase Cancer Center · 2 studies
- Geisinger Wyoming Valley/Henry Cancer Center · 2 studies
- Thomas Jefferson University Hospital · 2 studies
- Abington Memorial Hospital
- Allegheny Health Network
- Alliance Cancer Specialists
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 839 recruiting cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.